Press release
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ET NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex”
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ET\nNEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023. Management will host a conference call on Monday November 27, 2023, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session. Webcast / Conference Call Information: The live webcast of the conference call will be available on Anavex’s website at www.anavex.com. The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 860 5505 7787 and reference passcode 146807. A replay of the conference call will also be available on Anavex’s website for up to 30 days. About Anavex Life Sciences Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epile...